95734-82-0N.N.O=C([O-])C[O-].[Pt+2]GYAVMUDJCHAASE-UHFFFAOYSA-MNedaplatin is a second generation platinum analog. It is less nephrotoxic than [DB00515] but has proven equally effective. It was approved for use in Japan in 1995.
95734-82-0安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。
As a platinum analog, nedaplatin likely works similarly to [DB00515] on which the following mechanistic description is based. Once it has entered the cell it is hydrolyzed to its active form which complexes with water molecules. This form binds to to nucleophiles in the cytoplasm such as glutathione and other cyteine rich proteins resulting in an overall increase in oxidative stress as the cell loses antioxidant proteins. It also binds to purine nucleotides in the DNA. The active form allows for two binding interactions to form cross-links between these nucleotides. High mobility group proteins-1 and -2 induce apoptosis in response to guanine cross-links and their binding serves to shield the cross-linked DNA from repair mechanisms. The mismatch repair (MMR) protein complex also recognizes the distortion caused by platinum complexes and attempts to repair the DNA. This results in single strand breaks when the MMR complex attempts to remove the platinum cross-link. The MMR complex induces apoptosis after the repair attempt has failed. The single strand break in DNA makes it easier to form lethal double strand breaks with radiation treatment thus creating the radiosensitizing effect of nedaplatin.
Most of the platinum from nedaplatin is eliminated in the urine (59.6%).
The volume of distribution of free platinum is 12.0 L.
Clearance of the free platinum is 4.47 L/h.
用途DNA 鎖内及び鎖間で DNA 架 橋を形成し、DNA の複製及び転写阻害作用を 示します。
説明Nedaplatin, a novel second generation platinum complex, was marketed in Japan for the treatment of a variety of cancers including: head and neck, small-cell and non-small cell lung, oesophageal, prostatic, testicular, ovarian, cervical, bladder, and uterine cancers. Platinum anticancer agents, prototyped by cisplatin, have been reported to be hydrolyzed to the mono- or diaquated species of diamine platinum which react with nucleophilic sites on DNA to cause intrastrand and interstrand crosslinks and DNA-protein crosslinks, which result in cytotoxicity. Nedaplatin was reportedly more active than cisplatin against several solid tumors while sharing less nephro- and gastrointestinal toxicity to cisplatin in viva The minimal renal toxicity displayed by nedaplatin allows its use in patients with deteriorated renal function.
現在のフィルター条件では反応記録がありません。
読み込み中…
使用Nedaplatin is a platinum complex that has potent antineoplatic activity.